124 related articles for article (PubMed ID: 38051741)
21. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the
Kong A; Good J; Kirkham A; Savage J; Mant R; Llewellyn L; Parish J; Spruce R; Forster M; Schipani S; Harrington K; Sacco J; Murray P; Middleton G; Yap C; Mehanna H
BMJ Open; 2020 Mar; 10(3):e033009. PubMed ID: 32184305
[TBL] [Abstract][Full Text] [Related]
22. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma.
Liu J; Oza AM; Colombo N; Oaknin A
Int J Gynecol Cancer; 2022 Jan; 32(1):89-92. PubMed ID: 34716177
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
25. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Falchook GS; Sachdev J; Imedio ER; Kumar S; Mugundu GM; Jenkins S; Chmielecki J; Jones S; Spigel DR; Johnson M
Invest New Drugs; 2023 Jun; 41(3):493-502. PubMed ID: 37171722
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
27. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK
Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
du Bois A; Lück HJ; Bauknecht T; Möbus V; Bochtler H; Diergarten K; Meerpohl HG
Ann Oncol; 1997 Apr; 8(4):355-61. PubMed ID: 9209665
[TBL] [Abstract][Full Text] [Related]
29. WEE1 Inhibitor: Clinical Development.
Kong A; Mehanna H
Curr Oncol Rep; 2021 Jul; 23(9):107. PubMed ID: 34269904
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R; Stover DG; Lustberg MB; Shoben A; Zhao M; Mrozek E; Layman RM; Macrae E; Duan W; Zhang J; Hall N; Wright CL; Gillespie S; Berger M; Chalmers JJ; Carey A; Balasubramanian P; Miller BL; Amaya P; Andreopoulou E; Sparano J; Shapiro CL; Villalona-Calero MA; Geyer S; Chen A; Grever MR; Knopp MV; Ramaswamy B
Oncologist; 2020 Aug; 25(8):e1158-e1169. PubMed ID: 32452601
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
33. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
[TBL] [Abstract][Full Text] [Related]
34. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
36. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
Pasqualini C; Rubino J; Brard C; Cassard L; André N; Rondof W; Scoazec JY; Marchais A; Nebchi S; Boselli L; Grivel J; Aerts I; Thebaud E; Paoletti X; Minard-Colin V; Vassal G; Geoerger B
Eur J Cancer; 2021 Jun; 150():53-62. PubMed ID: 33892407
[TBL] [Abstract][Full Text] [Related]
37. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
39. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring
Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F
J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
